270 related articles for article (PubMed ID: 34044280)
1. The current understanding on the impact of KRAS on colorectal cancer.
Meng M; Zhong K; Jiang T; Liu Z; Kwan HY; Su T
Biomed Pharmacother; 2021 Aug; 140():111717. PubMed ID: 34044280
[TBL] [Abstract][Full Text] [Related]
2. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.
Zhu G; Pei L; Xia H; Tang Q; Bi F
Mol Cancer; 2021 Nov; 20(1):143. PubMed ID: 34742312
[TBL] [Abstract][Full Text] [Related]
3. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
[TBL] [Abstract][Full Text] [Related]
4. RAS mutation: site of disease and recurrence pattern in colorectal cancer.
Bonnot PE; Passot G
Chin Clin Oncol; 2019 Oct; 8(5):55. PubMed ID: 31597436
[TBL] [Abstract][Full Text] [Related]
5. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
6. Review: KRAS mutations are influential in driving hepatic metastases and predicting outcome in colorectal cancer.
Steele CW; Whittle T; Smith JJ
Chin Clin Oncol; 2019 Oct; 8(5):53. PubMed ID: 31597434
[TBL] [Abstract][Full Text] [Related]
7. Impact of KRAS mutation on the tumor microenvironment in colorectal cancer.
Zhou Y; Kuang Y; Wang C; Yu Y; Pan L; Hu X
Int J Biol Sci; 2024; 20(5):1947-1964. PubMed ID: 38481800
[TBL] [Abstract][Full Text] [Related]
8. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
9. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
10. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines.
Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
Metabolomics; 2020 Apr; 16(4):51. PubMed ID: 32300895
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive KRAS mutation estimation in colorectal cancer using a deep learning method based on CT imaging.
He K; Liu X; Li M; Li X; Yang H; Zhang H
BMC Med Imaging; 2020 Jun; 20(1):59. PubMed ID: 32487083
[TBL] [Abstract][Full Text] [Related]
13. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
14. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
15. Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology.
László L; Kurilla A; Takács T; Kudlik G; Koprivanacz K; Buday L; Vas V
Cells; 2021 Mar; 10(3):. PubMed ID: 33802849
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: Direct and indirect comparison meta-analysis.
Kwak MS; Cha JM; Yoon JY; Jeon JW; Shin HP; Chang HJ; Kim HK; Joo KR; Lee JI
Medicine (Baltimore); 2017 Sep; 96(35):e7882. PubMed ID: 28858102
[TBL] [Abstract][Full Text] [Related]
17. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
18. Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review.
Bteich F; Mohammadi M; Li T; Bhat MA; Sofianidi A; Wei N; Kuang C
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569406
[TBL] [Abstract][Full Text] [Related]
19. Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer.
Yokota T; Shibata N; Ura T; Takahari D; Shitara K; Muro K; Yatabe Y
Transl Res; 2010 Aug; 156(2):98-105. PubMed ID: 20627194
[TBL] [Abstract][Full Text] [Related]
20. Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes.
Amitay EL; Carr PR; Jansen L; Walter V; Roth W; Herpel E; Kloor M; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M
J Natl Cancer Inst; 2019 May; 111(5):475-483. PubMed ID: 30388256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
